EBS

SEC source: 0001140361-17-001760 · doc1.xml · derivative · entry 7

Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,662

Underlying: Common Stock · 38,006 shares

Expires 2017-03-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated prior to the Spin-off.

F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-001760 · doc1.xml · nonDerivative · entry 5

Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,162

F4 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.91 to $32.26, inclusive.

SEC source: 0001140361-17-001760 · doc1.xml · nonDerivative · entry 4

Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,402

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.

SEC source: 0001140361-16-089899 · doc1.xml · nonDerivative · entry 5

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,151

SEC source: 0001140361-16-089899 · doc1.xml · nonDerivative · entry 4

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,251

SEC source: 0001140361-16-085896 · doc1.xml · nonDerivative · entry 1

Zoon Kathryn C · CIK 0001685720 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,226

F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.

F2 · shares: The restricted stock units vest in three equal annual tranches beginning in November 2017.

SEC source: 0001140361-16-089899 · doc1.xml · nonDerivative · entry 3

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,051

F3 · security: In connection with the spin-off (the "Spin-off") of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc. ("Emergent"), on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the Spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019.

SEC source: 0001140361-16-089899 · doc1.xml · nonDerivative · entry 2

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,474

F2 · security: In connection with the spin-off (the "Spin-off") of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc. ("Emergent"), on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the Spin-off. The restricted stock units vest in May 2017 and May 2018.

SEC source: 0001140361-16-089899 · doc1.xml · nonDerivative · entry 1

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,870

F1 · security: In connection with the spin-off (the "Spin-off") of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc. ("Emergent"), on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the Spin-off. The restricted stock units vest in May 2017.

SEC source: 0001140361-17-001760 · doc1.xml · derivative · entry 6

Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,668

Underlying: Common Stock · 3,662 shares

Expires 2017-03-08

F6 · security: Represents options to purchase Emergent common stock awarded to the reporting person prior to the Spin-off . In connection with the Spin-off, the number of shares and exercise price of the option was adjusted, to preserve the pre-Spin-off intrinsic value of the existing Emergent option award.

F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-001760 · doc1.xml · nonDerivative · entry 3

Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,396

F3 · security: In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019.

SEC source: 0001140361-17-001760 · doc1.xml · nonDerivative · entry 2

Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,977

F2 · security: In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018.

SEC source: 0001140361-17-001760 · doc1.xml · nonDerivative · entry 1

Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,945

F1 · security: In connection with the spin-off (the "Spin-off") of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc. ("Emergent"), on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the Spin-off. The restricted stock units vest in March 2017.

SEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 26

Bailey Sue · CIK 0001403769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,305

Underlying: Common Stock · 905 shares

Expires 2021-05-21

F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 24

Bailey Sue · CIK 0001403769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,893

Underlying: Common Stock · 693 shares

Expires 2020-05-22

F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 22

Bailey Sue · CIK 0001403769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,893

Underlying: Common Stock · 693 shares

Expires 2019-05-16

F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 20

Bailey Sue · CIK 0001403769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,736

Underlying: Common Stock · 416 shares

Expires 2021-05-18

F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 18

Bailey Sue · CIK 0001403769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,157

Underlying: Common Stock · 277 shares

Expires 2020-05-19

F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 16

Bailey Sue · CIK 0001403769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,157

Underlying: Common Stock · 277 shares

Expires 2019-05-20

F6 · security: In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 3

Bailey Sue · CIK 0001403769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,818

F3 · security: In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019.

SEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 2

Bailey Sue · CIK 0001403769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,241

F2 · security: In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018.

SEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 1

Bailey Sue · CIK 0001403769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,637

F1 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017.

SEC source: 0001140361-17-002340 · doc1.xml · derivative · entry 9

Havey Adam · CIK 0001514588 · EVP, Biodefense Divison

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,009

Underlying: Common Stock · 1,495 shares

Expires 2023-02-28

F10 · security: Consists of an option granted on 03/01/2016 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F7 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-002340 · doc1.xml · derivative · entry 8

Havey Adam · CIK 0001514588 · EVP, Biodefense Divison

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,414

Underlying: Common Stock · 1,794 shares

Expires 2022-03-09

F9 · security: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F7 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-002340 · doc1.xml · derivative · entry 7

Havey Adam · CIK 0001514588 · EVP, Biodefense Divison

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,828

Underlying: Common Stock · 2,709 shares

Expires 2021-03-10

F8 · security: Consists of an option granted on 03/11/2014 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F7 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-002340 · doc1.xml · derivative · entry 6

Havey Adam · CIK 0001514588 · EVP, Biodefense Divison

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,770

Underlying: Common Stock · 1,386 shares

Expires 2018-03-14

F6 · security: Consists of an option granted on 03/15/2011 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F7 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-002340 · doc1.xml · derivative · entry 5

Havey Adam · CIK 0001514588 · EVP, Biodefense Divison

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,573

Underlying: Common Stock · 577 shares

Expires 2018-03-14

F6 · security: Consists of an option granted on 03/15/2011 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F7 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-002340 · doc1.xml · nonDerivative · entry 3

Havey Adam · CIK 0001514588 · EVP, Biodefense Divison

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,771

F3 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019.

SEC source: 0001140361-17-002340 · doc1.xml · nonDerivative · entry 2

Havey Adam · CIK 0001514588 · EVP, Biodefense Divison

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,023

F2 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018.

SEC source: 0001140361-17-002340 · doc1.xml · nonDerivative · entry 1

Havey Adam · CIK 0001514588 · EVP, Biodefense Divison

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,424

F1 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017.

SEC source: 0001140361-17-010396 · doc1.xml · derivative · entry 9

Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,397

Underlying: Common Stock · 2,847 shares

Expires 2023-02-28

F9 · security: Consists of an option granted on 03/01/2016 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F6 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-010396 · doc1.xml · derivative · entry 8

Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,132

Underlying: Common Stock · 2,847 shares

Expires 2022-03-09

F8 · security: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F6 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-010396 · doc1.xml · derivative · entry 7

Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,026

Underlying: Common Stock · 1,672 shares

Expires 2021-03-10

F7 · derivative.exercise_date: Consists of an option granted on 03/11/2014 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

SEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 3

Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,486

F3 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019.

SEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 2

Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,061

F2 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018.

SEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 1

Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

F1 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017.

SEC source: 0001140361-17-011623 · doc1.xml · derivative · entry 5

Hauer Jerome M · CIK 0001294935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,305

Underlying: Common Stock · 10,305 shares

Expires 2022-01-21

F5 · security: Consists of an option granted on January 22, 2015 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F6 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-011623 · doc1.xml · nonDerivative · entry 3

Hauer Jerome M · CIK 0001294935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,585

F3 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019.

SEC source: 0001140361-17-011623 · doc1.xml · nonDerivative · entry 2

Hauer Jerome M · CIK 0001294935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,008

F2 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018.

SEC source: 0001140361-17-011623 · doc1.xml · nonDerivative · entry 1

Hauer Jerome M · CIK 0001294935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,404

F1 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in January 2018.

SEC source: 0001140361-17-022459 · doc1.xml · derivative · entry 6

JOULWAN GEORGE A · CIK 0001222197 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,305

Underlying: Common Stock · 10,305 shares

Expires 2021-05-22

F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F8 · derivative.exercise_date: The option grant vests in May 2017.

SEC source: 0001140361-17-022459 · doc1.xml · derivative · entry 5

JOULWAN GEORGE A · CIK 0001222197 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,946

Underlying: Common Stock · 3,946 shares

Expires 2020-07-17

F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F7 · derivative.exercise_date: The option grant is fully vested.

SEC source: 0001140361-17-022459 · doc1.xml · nonDerivative · entry 3

JOULWAN GEORGE A · CIK 0001222197 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,118

F3 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019.

SEC source: 0001140361-17-022459 · doc1.xml · nonDerivative · entry 2

JOULWAN GEORGE A · CIK 0001222197 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,541

F2 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018.

SEC source: 0001140361-17-022459 · doc1.xml · nonDerivative · entry 1

JOULWAN GEORGE A · CIK 0001222197 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,937

F1 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017.

SEC source: 0001140361-17-022461 · doc1.xml · derivative · entry 9

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,305

Underlying: Common Stock · 10,305 shares

Expires 2021-05-22

F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

SEC source: 0001140361-17-022461 · doc1.xml · derivative · entry 8

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,893

Underlying: Common Stock · 7,893 shares

Expires 2020-05-23

F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F7 · derivative.exercise_date: The option grant is fully vested.

SEC source: 0001140361-17-022461 · doc1.xml · derivative · entry 7

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,893

Underlying: Common Stock · 7,893 shares

Expires 2019-05-17

F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F7 · derivative.exercise_date: The option grant is fully vested.

SEC source: 0001140361-17-022461 · doc1.xml · derivative · entry 6

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,893

Underlying: Common Stock · 7,893 shares

Expires 2021-05-19

F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F7 · derivative.exercise_date: The option grant is fully vested.

SEC source: 0001140361-17-022461 · doc1.xml · derivative · entry 5

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,893

Underlying: Common Stock · 7,893 shares

Expires 2020-05-20

F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.

F7 · derivative.exercise_date: The option grant is fully vested.